07/20/2001

Natus Medical Announces Initial Public Offering

SAN CARLOS, Calif., Jul 20, 2001 (BUSINESS WIRE) – Natus Medical Incorporated ("Natus") (BABY) today announced the initial public offering of its common stock on the Nasdaq National Market under the symbol "BABY."

The initial public offering price for the 5,000,000 shares was $11 per share. All of the shares were offered and sold by Natus. The offering was led by Dain Rauscher Wessels and was co-managed by First Union Securities and Adams, Harkness & Hill.

Natus has granted the underwriters the option to purchase up to 750,000 additional shares to cover over-allotments, if any. A copy of the final prospectus may be obtained from the offices of Dain Rauscher Wessels, 60 South Sixth Street, Minneapolis, MN 55402-4422.

A registration statement relating to these securities was filed and declared effective by the Securities and Exchange Commission. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Natus Medical Incorporated

Natus develops, manufactures and markets proprietary, non-invasive, easy-to-use, crib-side screening devices for the detection and/or monitoring of common disorders in babies. Natus' ALGO® Newborn Hearing Screeners provide early detection of one of the most common chronic impairments in babies: hearing loss. The CO-Stat® End Tidal Breath Analyzer enables nurses and pediatricians to screen for and monitor the rate of bilirubin production in babies, a major factor in understanding the disease state of neonatal jaundice, one of the most common acute disorders in newborns. For more information, visit Natus' website at www.natus.com.

NOTE: ALGO and CO-Stat are registered trademarks of Natus. Natus also markets its products through wholly owned subsidiaries in the United Kingdom and in Japan, and through third parties in Australia, Belgium, Holland, New Zealand, Spain, Saudi Arabia and the United Arab Emirates.

Natus Medical Incorporated
Bill Lawrenson, 650/802-0400
www.natus.com
or
Investor Contact:
Lippert/Heilshorn & Associates
Bruce Voss, 310/691-7100
bvoss@lhai.com
www.lhai.com
or
Financial Media Contact:
Lippert/Heilshorn & Associates
Elissa Grabowski, 212/838-3777 Egrabowski@lhai.com
www.lhai.com